BIEL: A Rare Pre‑IPO‑Style VC Opportunity Entering Full Commercial Scale With Momentum (Recent 400% PPS Surge, Better Than 99.9% of All Stocks). Hypergrowth (Revenues Doubling Every Year) Justifies P/E = 1000
Institutional investors build generational wealth by entering companies before the public ever sees them. By the time a startup hits the Nasdaq, insiders have already captured 90% of the upside — retail gets the scraps.
BIEL is the exception. Even though it trades publicly at sub‑penny levels, BIEL offers the same asymmetric, ground‑floor risk‑to‑reward profile as a pre‑IPO venture capital investment — without accredited‑investor barriers, without million‑dollar checks, and without dilution risk from massive fundraising rounds. And now the first true commercial‑scale event is locked in.
The 3,700‑Store Retail Rollout: The Catalyst That VC Investors Dream AboutElectrome’s national pharmacy rollout — 3,700 stores beginning in late 2026 — is the moment BIEL transitions from “early‑stage tech” to “scaling revenue engine.” This is not speculation; the math is already defined in the rollout model:
Retail rollouts follow a predictable pattern: Pipeline Fill - Restock Velocity
Electrome cannot ship a single PAINKILLER™ unit without BIEL’s OEM hardware inside
OEM wholesale price is fixed at $15 per module
Phase 1 — Pipeline Fill (Late 2026)
5–10 units per store for initial shelf stocking
18,500–37,000 units required across 3,700 stores
$277,500–$555,000 in immediate OEM revenue to BIEL
Phase 2 — Restock Velocity (Full‑Year 2027)
2–4 units per store per month (conservative)
88,800–177,600 units annually
$1.33M–$2.66M annualized OEM revenue from retail alone
This sits on top of the $0.75M–$2.25M modeled for 2026 from VA deployments, pilot clinics, and onboarding programs .
This is exactly how early‑stage VC hypergrowth looks.
The Razor‑Blade Model: The Hidden Multiplier
Electrome’s platform uses BIEL’s core tech (ActiPatch/RecoveryRx) in both:
The initial PAINKILLER™ kit
The high‑margin replacement modules consumers buy later
This is the same recurring‑revenue structure that turned early medical‑device startups into billion‑dollar disruptors.
Revenue Has Already Started — This Is Not a Future Story
Electrome is already:
Deploying inside the U.S. Department of Veterans Affairs (largest healthcare system in America)
Shipping hardware for pilot clinics and onboarding programs
Generating OEM invoices for BIEL right now in 2026
The revenue clock is already running — and accelerating.
Profitability Math: Why the Valuation Gap Is Absurd
BIEL’s operating model is ultra‑lean:
Near‑zero operating costs
Every $3M revenue ≈ $2.5M profit (extreme conversion efficiency)
$40M tax‑loss carryforward accelerates net profitability
This is why early hypergrowth companies (that double revenues every year) often trade at P/E ratios above 1,000 — Amazon, Tesla, Salesforce, Zoom all did it during their breakout phases.
At $2.5M profit, BIEL could justify a $2.5B market cap — roughly $0.10 PPS.
PPS Roadmap (Based on Electrome US/Canada Only)
.001 — Technical breakout
.01 — Cash‑flow positive (requires $1–1.5M revenue)
.10 — $2.5M profit (achievable with $3M revenue)
$1.00 — After debt payoff + buybacks (2028)
A global BIEL / Electrome–Haleon contract would accelerate this timeline dramatically, as would significant revenues from Taiwan.
Final Takeaway
BIEL is the closest thing retail investors ever get to a true pre‑IPO venture‑capital ground floor — but with a commercial‑scale event already scheduled, already modeled, and already generating revenue.
This is what asymmetric opportunity looks like.
Institutional investors build generational wealth by entering companies before the public ever sees them. By the time a startup hits the Nasdaq, insiders have already captured 90% of the upside — retail gets the scraps.
BIEL is the exception. Even though it trades publicly at sub‑penny levels, BIEL offers the same asymmetric, ground‑floor risk‑to‑reward profile as a pre‑IPO venture capital investment — without accredited‑investor barriers, without million‑dollar checks, and without dilution risk from massive fundraising rounds. And now the first true commercial‑scale event is locked in.
The 3,700‑Store Retail Rollout: The Catalyst That VC Investors Dream AboutElectrome’s national pharmacy rollout — 3,700 stores beginning in late 2026 — is the moment BIEL transitions from “early‑stage tech” to “scaling revenue engine.” This is not speculation; the math is already defined in the rollout model:
Retail rollouts follow a predictable pattern: Pipeline Fill - Restock Velocity
Electrome cannot ship a single PAINKILLER™ unit without BIEL’s OEM hardware inside
OEM wholesale price is fixed at $15 per module
Phase 1 — Pipeline Fill (Late 2026)
5–10 units per store for initial shelf stocking
18,500–37,000 units required across 3,700 stores
$277,500–$555,000 in immediate OEM revenue to BIEL
Phase 2 — Restock Velocity (Full‑Year 2027)
2–4 units per store per month (conservative)
88,800–177,600 units annually
$1.33M–$2.66M annualized OEM revenue from retail alone
This sits on top of the $0.75M–$2.25M modeled for 2026 from VA deployments, pilot clinics, and onboarding programs .
This is exactly how early‑stage VC hypergrowth looks.
The Razor‑Blade Model: The Hidden Multiplier
Electrome’s platform uses BIEL’s core tech (ActiPatch/RecoveryRx) in both:
The initial PAINKILLER™ kit
The high‑margin replacement modules consumers buy later
This is the same recurring‑revenue structure that turned early medical‑device startups into billion‑dollar disruptors.
Revenue Has Already Started — This Is Not a Future Story
Electrome is already:
Deploying inside the U.S. Department of Veterans Affairs (largest healthcare system in America)
Shipping hardware for pilot clinics and onboarding programs
Generating OEM invoices for BIEL right now in 2026
The revenue clock is already running — and accelerating.
Profitability Math: Why the Valuation Gap Is Absurd
BIEL’s operating model is ultra‑lean:
Near‑zero operating costs
Every $3M revenue ≈ $2.5M profit (extreme conversion efficiency)
$40M tax‑loss carryforward accelerates net profitability
This is why early hypergrowth companies (that double revenues every year) often trade at P/E ratios above 1,000 — Amazon, Tesla, Salesforce, Zoom all did it during their breakout phases.
At $2.5M profit, BIEL could justify a $2.5B market cap — roughly $0.10 PPS.
PPS Roadmap (Based on Electrome US/Canada Only)
.001 — Technical breakout
.01 — Cash‑flow positive (requires $1–1.5M revenue)
.10 — $2.5M profit (achievable with $3M revenue)
$1.00 — After debt payoff + buybacks (2028)
A global BIEL / Electrome–Haleon contract would accelerate this timeline dramatically, as would significant revenues from Taiwan.
Final Takeaway
BIEL is the closest thing retail investors ever get to a true pre‑IPO venture‑capital ground floor — but with a commercial‑scale event already scheduled, already modeled, and already generating revenue.
This is what asymmetric opportunity looks like.
1
